The same characteristics are unfolding with NNVC.
What an opportunity I missed, being in the Med field, and knowing they were developing Hep B treatment, not available anywhere else. HIV met it's match with GILD. I applaud you guys at Gilead.
They are waiting to have a chance to Rape it down to $3. Good Luck
VJET is going below $35 sooner than later.
PLUS always counts it's Chicken before they hatch. This time, it is no different
I just noted same thing Street Authority just published. The potential is ENDLESS, including Acquisition by larger Companies